Text
Why timing matters
Screening is not about expecting bad news. It is about reducing uncertainty, and giving you and your clinician more options while there are more options to have.
Dr. Scott Tackett
President & CEO
For patients diagnosed at Stage IA, 5-year relative survival can be around 91%. For those diagnosed after the disease has progressed to late stages, that figure can fall below 15%.
The difference highlights an important reality: earlier detection can create opportunities for earlier intervention, broader treatment options and potentially better outcomes.
As conversations around cancer care continue to evolve, timing of detection and diagnosis remains one of the most important factors influencing a patient’s journey.
Sources: Goldstraw, P., et al. (2016). The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. Journal of Thoracic Oncology, 11(1), 39–51.
Originally shared on LinkedIn
Join the conversation and see how others have responded.
Advancing infrared applications for earlier detection — beginning with lung cancer.
AIR-DS is a UKCA marked in vitro diagnostic medical device, developed in accordance with IEC 62304 and under an ISO 13485 certified quality management system. In the US, a CLIA certified laboratory will offer a laboratory developed test (LDT) with AIR-DS Lung Test. It has not been cleared or approved by the FDA. Information on this website is provided for educational and informational purposes and should not be interpreted as medical advice.